File(s) under permanent embargo
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
Background: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease.
Methods: Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period.
Results: Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05).
Conclusions: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties.
History
Publication title
Movement DisordersVolume
26Issue
8Pagination
1552-1555ISSN
0885-3185Department/School
Wicking Dementia Research Education CentrePublisher
Wiley-LissPlace of publication
Div John Wiley & Sons Inc, 605 Third Ave, New York, USA, Ny, 10158-0012Repository Status
- Restricted